Twitter Beğeni Hilesi

#USProstateCancerConference OncLive.com at NYC👉 Esteemed group of investigators discussing challenging areas in treatment of #prostatecancer : Excellent talk by Jeremie Calais on PSMA PET impact in BCR setting. Alan H Bryce Phillip Koo, MD

#USProstateCancerConference Outstanding debate between Andrew Armstrong & Emmanuel Antonarakis on the use of PARPi+ARPI combo in HRRm + versus HRRm- patients👉balancing AEs with efficacy and looking for biomarkers in HRRm- pts👇Misha Beltran Alan H Bryce

Andrew Armstrong Emmanuel Antonarakis Misha Beltran Alan H Bryce Phillip Koo, MD Sandy Srinivas Michael Carducci Charles Ryan Tanya Dorff GU Cancer Research Program @HuntsmanCancer PCF Science Sumanta K. Pal, MD, FASCO Petros Grivas #USProstateCancerConference OncLive.com 👉Question: should serial tumor genomic testing be done in advanced #prostatecancer? Point and counterpoint by Rana McKay, MD, FASCO and #EvanYu 👇Misha Beltran

Andrew Armstrong Emmanuel Antonarakis Misha Beltran Alan H Bryce Phillip Koo, MD Sandy Srinivas Michael Carducci Charles Ryan Tanya Dorff GU Cancer Research Program @HuntsmanCancer PCF Science Sumanta K. Pal, MD, FASCO Petros Grivas OncLive.com Rana McKay, MD, FASCO Tian Zhang, MD, MHS Shilpa Gupta Daniel E Spratt #USProstateCancerConference Tian Zhang, MD, MHS and Alan H Bryce argue for or against ARPI+PARPi vs PARPi Mono Rx in metastatic #prostatecancer with HRRm after prior ARPI. Case can be made for both combo or PAPPi alone👇. OncLive.com Misha Beltran UroToday.com OncoAlert

Should we radiate the primary in high volume metastatic hormone sensitive #prostatecancer? #JasonEfstathiou says yes! Daniel E Spratt says maybe sometimes. Patient selection based on biology seems a happy medium. #USProstateCancerConsortium OncLive.com Prostate Cancer Foundation Neeraj Agarwal, MD, FASCO

Very important paper confirming surrogacy of cPFS and rPFS in mHSPC with OS. Great work. We need ICE!!! ⁦Michael Morris⁩ ⁦The PCCTC⁩ ⁦Christopher Sweeney, MBBS⁩

Always a privilege to work with Alicia Morgans, MD, MPH and the UroToday.com team. Thank you for being committed to spreading educational content in GU Cancers

Few investigators today have had as significant an impact on the world of prostate cancer researchers as Felix Feng Please donate to this Conquer Cancer Foundation YIA in his honor.

Network with City of Hope leaders during the 2024 ASCO Annual Meeting! R.S.V.P. by Sunday, May 26, to [email protected] or 626-218-5622. More info: CityofHope.org/ASCO24. #ASCO24

One of the first of many podiums to come for Irbaz Riaz MD,MS,MBI,PhD as the field recognizes impact of his work in AI and prostate cancer.

Proud of our work published today in Nature Medicine, sharing results from our phase 1 trial with PSCA-CAR T cell therapy in patients with mCRPC. Big collaborations work Tanya Dorff @stephenforman Peter Kuhn Lior Pachter ! Thank you Prostate Cancer Foundation for your support! nature.com/articles/s4159…

Researchers at City of Hope are advancing treatment for advanced prostate cancer with immunotherapy. Early results from a phase 1 trial using CAR T cell therapy showed minimal side effects and promising activity, as reported in Nature Medicine. cityofhope.org/study-car-t-pr…

City of Hope Medical Center - Fellowship Opening -July 2025 (1 and 2 year positions ). Urologic Oncology Wonderful diverse faculty and research opportunity. Kevin Chan, MD Wesley Yip Jonathan Yamzon Ali Zhumkhawala, MD Cory Hugen Jeff Yoshida Seth Cohen Claire Burton MD City of Hope Surgery COH Urologic Oncology

Lurbinectedin comes from a sea squirt and is approved for small cell lung cancer. Is it active in NEPC? See our retrospective experience here, just published! sciencedirect.com/science/articl… DCI Center for Prostate & Urologic Cancers Alan H Bryce Misha Beltran great work Haley Meyer!

🔥🚨OncoAlert Hot off the press. Just published NEJM in conjunction with presentation ESMO - Eur. Oncology #ESMO24 Results of #Positive Phase 2 trial of #Ponsegromab (#GDF15 inhibitor) vs #Placebo for treatment of #Cachexia in patients with #Cancer. 👇🏼 nejm.org/doi/full/10.10…

PFS and OS advantage of radium-223 + Enza vs Enza alone in metastatic prostate cancer—-new combo on the horizon —congrats silke gillessen and PEACE-3 team. No increased SREs! ESMO - Eur. Oncology #ESMO2024

Outstanding talk from silke gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 ESMO - Eur. Oncology OncoAlert UroToday.com

Incorporating PSMA PET/CT into PCWG4: preliminary work from the PRINCE trial #ESMO24 See the KM curves on the top-right: PCWG3 curve using CT & bone scan touches the overall survival curve as time goes on. That is because patients die before having PCWG3 radiographic

Full house for Tom Powles ‘s presidential talk of the results of the ph3 NIAGARA trial w/ neo-adj durva + gem-cis followed by surgery + adj durva in pts w/ MIBC #bladdercancer 👇🏻 ⭐️ HR 0.68 for EFS (primary endpoint) & 0.75 for OS ⭐️ pCR 37.3% w/ Durva UroToday.com OncoAlert

STAMPEDE: Decipher score predictive of OS treatment benefit with docetaxel addition to ADT in both low & high volume pts 📌2nd predictive biomarker in PCa space, following ArteraAI for ST-ADT intensification in int risk pts receiving XRT UroToday.com #ESMO24